EDIT
NASDAQ · Biotechnology
Editas Medicine Inc
$2.82
+0.01 (+0.36%)
Open$2.81
Previous Close$2.81
Day High$2.85
Day Low$2.72
52W High$4.54
52W Low$1.66
Volume—
Avg Volume1.52M
Market Cap444.03M
P/E Ratio—
EPS$-1.22
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+354.3% upside
Current
$2.82
$2.82
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 78.58M | 61.80M | 30.54M |
| Net Income | -310,408,368 | -219,714,928 | 4.38M |
| Profit Margin | -395.0% | -375.3% | 14.4% |
| EBITDA | -300,082,075 | -224,206,033 | 9.59M |
| Free Cash Flow | — | — | 5.15M |
| Rev Growth | +27.2% | +27.2% | +16.6% |
| Debt/Equity | 2.15 | 2.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |